MedCityNews reports that pharma moving slowly into emerging field of digital health. According to one speaker at a recent digital health panel discussion, “pharma is multiple generations behind the clinic in using digital.” Big pharma tends to be risk averse and “are painfully slow” the speaker went on. But change is on the horizon. As TrialSite News recently highlighted in a blog posting focusing on digital health, Roche recently spent $1.9 billion to acquired New York-based Flatiron Health, a healthcare technology company focusing on oncology. As we have showcased in the Digital Health roundup, big pharma increasingly partners, invests or buys technologies to position itself for the future and for today.
View article here